Eli Lilly and Company Aktie News

Eli Lilly and Viking Therapeutics both operate in the high-growth field of obesity drugs. This market is forecast to reach almost $100 billion by the end of the decade.

Eli Lilly has made several moves to boost its artificial intelligence (AI) capacity. It could help complement its strong innovative capabilities.

Novo Nordisk was excessively punished by the market, trading at a significant discount to Eli Lilly despite robust fundamentals and global leadership in metabolic disease. NVO's global infrastructure, especially outside the U.S., and its oral GLP-1 program position it for long-term relevance as obesity pharmacotherapy expands worldwide. Recent valuation divergence was more amplified by retail-d...

Eli Lilly's oral GLP-1 candidate, orforglipron, won't earn approval as fast as the company expected. Meanwhile, a notable competitor is making headway in this market.

These trillion-dollar stocks may be setting up for their next move.

NEW YORK and NEW ORLEANS, Jan. 23, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

Eli Lilly is at the forefront of the GLP-1 weight loss drug market. The company's leading position is already being tested by Novo Nordisk's GLP-1 weight loss pill.

Eli Lilly stock has been climbing back from a recent pullback and nearing a buy point. The drugmaker teamed up with Nvidia on a new project.